Abstract
The metabolic fate of the anti-Parkinsonian drug budipine was studied in rats after oral administration. The presence of an aromatic hydroxylation product, metabolite Mi, and its O-sulphate conjugate was confirmed. Three new minor metabolites, budipine N-oxide, metabolite M1 N-oxide and a secondary metabolite derived from M1 via hydroxylation of a methyl of the tert-butyl group, were isolated and identified in rat urine. The presence of a metabolite M1-glucuronic acid conjugate, was also established through different enzymatic treatments of the rat urine.
| Original language | English |
|---|---|
| Pages (from-to) | 113-118 |
| Number of pages | 6 |
| Journal | European Journal of Drug Metabolism and Pharmacokinetics |
| Volume | 16 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Apr 1991 |
| Externally published | Yes |
Keywords
- 1-tert-butyl-4,4-diphenylpiperidine
- BY-701
- Budipine
- anti-Parkinsonian
- metabolism
Fingerprint
Dive into the research topics of 'The metabolic fate of the anti-Parkinsonian drug budipine in rats'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver